PS2 mRNA expression adds prognostic information to node status for 6-year survival in breast cancer

British Journal of Cancer

Volumn 77, Issue 3, 1998, Pages 492-496

  Thompson, A M ^a   Elton, R A ^b   Hawkins, R A ^b   Chetty, U ^c   Steel, C M ^d  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^c WESTERN GENERAL HOSPITAL   (United Kingdom)

^d UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

Breast cancer; Prognosis; pS2

Indexed keywords

ESTROGEN RECEPTOR; MESSENGER RNA; PROTEIN PS2; TAMOXIFEN;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; NORTHERN BLOTTING; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS;

EID: 0031983092     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.78     Document Type: Article

References (35)

1. Anderson EDC, Forrest APM, Levack PA, Chetty U and Hawkins RA (1989) Response to endocrine manipulation and oestrogen receptor concentration in large operable primary breast cancer. Br J Cancer 60: 223-226
2. Carr M, May FEB, Lennard TWJ and Westley BR (1995) Determination of oestrogen responsiveness of breast cancer by competitive reverse transcription polymerase chain reaction. Br J Cancer 72: 1427-1434
3. Coradini D, Biganzoli E, Boracchi P, Martelli G and Di Fronzo G (1996) Predictive role of steroid receptors pS2 and Cathepsin D on the outcome of elderly breast cancer patients. Br Can Res Treat 41: 249
4. Delvenne CG, Winkler-Gol RA, Piccart MJ, Hustin J, Michaux D, Leclerecq G, Nogaret JM and Autier P (1992) Expression of c-erbB2, TGF-beta 1 and pS2 genes in primary human breast cancers. Eur J Cancer 28: 700-705
5. Detre S, King N, Salter S, MacLennan K, McKinna JA and Dowsett M (1994) Immunohistochemical and biochemical analysis of the oestrogen regulated protein pS2, and its relation with oestrogen receptor and progesterone receptor in breast cancer. J Clin Pathol 47: 240-244
6. Foekens JA, Rio M-C, Seguin P, Putten WLJ, Van Fauque I, Nap M, Kiljn JGM and Chambon P (1990) Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res 50: 3832-3837
7. Foekens JA, Portengen H, Look MP, van Putten WLJ, Thirion B, Bontenbal M and Kiljn JGM (1994) Relationship of pS2 with response to tamoxifen therapy in patients with recurrent breast cancer. Br J Cancer 70: 1217-1223
8. Gibert OD, Machuca I, Sebastian MA, Rosel P and Navarro MA (1996) pS2 is a useful predictor of regression in tamoxifen therapy. Med Clin 107: 90-92
9. Gion M, Mione R, Pappagallo GL, Gatti C, Nascimben O, Bari M, Leon AE, Vinante O and Bruscagnin G (1993) pS2 in breast cancer - alternative or complementary tool to steroid receptor status? Evaluation of 446 cases. Br J Cancer 68: 374-379
10. Hahnel E, Joyce R, Sterrett C, Harvey I and Hahnel R (1991) Detection of estradiol-induced messenger RNA (pS2) in uninvolved breast tissue from mastectomies for breast cancer. Br Cancer Res Treat 20: 167-176
11. Henry JA, Nicholson S, Farndon JR, Westley BR and May FEB (1988) Measurement of oestrogen receptor mRNA levels in human breast tumours. Br J Cancer 58: 600-605
12. Henry JA, Nicholson S, Hennessy C, Lennard TWJ, May FEB and Westley BR (1990) Expression of the oestrogen regulated pNR-2 mRNA in human breast cancer: relation to oestrogen receptor mRNA levels and response to tamoxifen therapy. Br J Cancer 61: 32-38
13. Henry JA: Piggott NH, Mallick UK, Nicholson S, Farndon JR, Westley BR and May FEB (1991) pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response. Br J Cancer 63: 615-622
14. Kardas I, Seitz G, Limon J, Niezabitowski A, Rys J, Theisinger B, Welter C and Blin N (1993) Retrospective analysis of prognostic significance of the estrogen-inducible pS2 gene in male breast cancer. Cancer 72: 1652-1656
15. Kausitz J, Kuliffay P, Pecen L, Eben K and Puterova B (1994) Correlation of cytosolic concentrations of ER, PS2, Cath-D, TPS, TK and cAMP in primary breast carcinomas. Neoplasma 41: 331-336
16. Masiakowski P, Breathnach R, Bloch I, Gannon F, Krust A and Chambon P (1982) Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res 10: 7895-7903
17. Minty A, Caravatti M, Robert B, Cohen A, Daubas P, Weydert A, Gros F and Buckingham ME (1981) Mouse actin messenger RNAs. J Biol Chem 256: 1008-1014
18. Predine I, Spyratos F, Prud-Homme JF, Andrieu C, Hacene K, Brunet M, Pallud C and Milgrom E (1992) Enzyme-linked immunosorbent assay of pS2 in breast cancers, benign tumours, and normal breast tissues. Cancer 69: 2116-2123
19. Ramm S, Robert N, Pappas CA and Tamura H (1988) Defective estrogen receptors in human mammary cancers: their significance in defining hormone dependence. J Natl Cancer Inst 80: 756-761
20. Rio MC, Bellocq JP, Gairard B, Rasmussen UB, Krust A, Koehl C, Calderoli H, Schiff V, Renaud R and Chambon P (1987) Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene ERBB2. Proc Natl Acad Sci USA 84: 9243-9247
21. Schmidt R, Sorger D, Walter F, Schonfelder M and Preiss R (1996) pS2 protein, EGFR and Cathepsin-D in association with established prognostic factors in early recurrence of breast cancer. Onkologie 19: 176-180
22. Schwartz LH, Koerner FC, Edgerton SM, Sawicka JM, Rio MC, Bellocq JP, Chambon P and Thor AD (1991) pS2 expression and response to hormonal therapy in patients with advanced breast cancer. Cancer Res 51: 624-628
23. Skilton RA, Luqmani YA, McClelland RA and Coombes RC (1989) Characterisation of a messenger RNA selectively expressed in human breast cancer. Br J Cancer 60: 168-175
24. Soubeyran I, Quenel N, Maurie L, Durand M, Bonichon F and Coindre J-M (1996) Variation of hormonal receptor, pS2, c-erbB-2 and GSTpi contents in breast carcinomas under tamoxifen: a study of 74 cases. Br J Cancer 73: 735-743
25. Speiser P, Stoizlechner S, Haider K, Heinzi H, Jakesz R, Pecherstorfer M, Rosen H, Sevelda P and Zeilliger R (1994) pS2 protein status fails to be an independent prognostic factor in an average breast cancer population. Anticancer Res 14: 2125-2130
26. Stack G, Kumar V, Green S, Ponglikitmongkol M, Berry M, Rio MC, Nunez AM, Roberts M, Bellocq P, Gairard B, Renaud R and Chambon P (1988) Structure and function of the pS2 gene and estrogen receptor in human breast cancer cells. In Breast Cancer: Cellular and Molecular Biology, Lippmann ME and Dickson RB. (eds), pp. 185-206, Kluwer: Boston
27. Stonelake PS, Baker PG, Gillespie WM, Dunn JA, Spooner D, Morrison JM, Bundred NJ, Oates GD, Lee MJ and Neoptolemos JP (1994) Steroid receptors, p52 and cathepsin D in early clinically node-negative breast cancer. Eur J Cancer 30: 5-11
28. Thompson AM, Hawkins RA, Elton RA, Steel CM, Chetty U and Carter DC (1993) pS2 is an independent factor of good prognosis in primary breast cancer. Br J Cancer 68: 93-96
29. Tutschek B, Niederacher D, Caminada MC, Gohring UJ, Schaol A, Schnurch HG, Beckman MW and Bender HG (1996) pS2 protein detected by immunohistochemistry in archival primary breast cancer prognostic value and long term follow-up in 219 patients. Oncol Rep 3: 759-764
30. Walker RA, Rajakariar R and Dookeran KA (1995) Comparison of pS2 and cathepsin D in primary breast carcinomas. The Breast 4: 137-142
31. Westley B and May FEB (1991) Estrogen-related messenger RNAs in human breast cancer cells. Cancer Treat Res 53: 259-271
32. Willsher PW. Gee JMW, Blamey RW, Nicolson RI and Robertson JFR (1996) Changes in ER, PgR and pS2 protein during tamoxifen therapy for primary breast cancer. Br Cancer Res Treat 41: 288
33. Wilson YG, Rhodes M, Ibrahim NBN, Padfield CJH and Cawthorn SJ (1994) Immunocytochemical staining of ps2 protein in fine-needle aspirate from breast cancer is an accurate guide to response to tamoxifen in patients aged over 70 years. Br J Surg 81: 1155-1158
34. Wysocki SJ, Iacopetta BJ and Ingram DM (1994) Prognostic significance of pS2 mRNA in breast cancer. Eur J Cancer 30A: 1882-1884
35. Zaretsky JZ, Weiss M, Tsarfaty I, Hareuveni M, Wreschner DH and Keydar I (1990) Expression of genes coding for pS2, c-erbB2, estrogen receptor and the H23 breast tumour associated antigen. FEBS Lett 265: 46-50